Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02296125 · OUTCOME

Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Items (EORTC QLQ-C30)

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer · Source last updated 2026-04-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
LEAST_SQUARES_MEAN
Unit
Unit on scale
Interval / dispersion
95% Confidence Interval
Time frame
Questionnaires completed at baseline, first 9 months, and at week 6, 12, 18, 24, 30, and 36.

What was measured

The EORTC QLQ-C30 cancer-specific questionnaire consisted of 30 questions, combined to produce 5 functional scales, 3 symptom scales, 6 individual items, and a global measure of health status/QoL. An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items, the functional scales, and the global health status/QoL scale in the EORTC QLQ-C30. Higher scores on the global health status and functioning scales indicated better health status/function. Higher scores on the symptoms scales indicated greater symptom burden. The analysis was performed using a Mixed-effects model for repeated measures analysis on the change from baseline in PRO symptom score at each visit up to 9 months (281 days), including participants, treatment, visit and treatment by visit interaction as explanatory variables, the baseline PRO score as a covariate along with the baseline PRO score by visit interaction, using an unstructured covariance structure.

Analysis population: The full analysis set (FAS) and China-only FAS. FAS included all randomized participants prior to the end of global recruitment. The China-only FAS included all China participants randomized in mainland-China as part of the global study and all additional China participants recruited in mainland China after global recruitment was completed.

Groups in this outcome

Osimertinib 80 mg (Global Cohort)

Randomized participants received Osimertinib 80 mg orally once daily (QD)

SoC EGFR-TKI (Global Cohort)

Randomized participant received Standard of care (SoC) Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Participants received gefitinib 250 mg orally QD or erlotinib 150 mg orally QD.

Osimertinib 80 mg (China Cohort)

Randomized participants received Osimertinib 80 mg orally once daily (QD)

SoC EGFR-TKI (China Cohort)

Randomized participant received Standard of care (SoC) Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFRTKI). Participants received gefitinib 250 mg orally QD or erlotinib 150 mg orally QD.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Osimertinib 80 mg (Global Cohort)279
SoC EGFR-TKI (Global Cohort)277
Osimertinib 80 mg (China Cohort)71
SoC EGFR-TKI (China Cohort)65

Reported measurements

Fatigue, First 9 months

Analysis denominator · Participants

GroupSource count
Osimertinib 80 mg (Global Cohort)252
SoC EGFR-TKI (Global Cohort)247
Osimertinib 80 mg (China Cohort)68
SoC EGFR-TKI (China Cohort)63
Values in Unit on scale · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Osimertinib 80 mg (Global Cohort)-5.48Not reported-7.45-3.52Not reported
SoC EGFR-TKI (Global Cohort)-4.72Not reported-6.74-2.69Not reported
Osimertinib 80 mg (China Cohort)-5.65Not reported-9.33-1.98Not reported
SoC EGFR-TKI (China Cohort)-5.79Not reported-9.58-2.00Not reported
Fatigue, week 6

Analysis denominator · Participants

GroupSource count
Osimertinib 80 mg (Global Cohort)239
SoC EGFR-TKI (Global Cohort)236
Osimertinib 80 mg (China Cohort)68
SoC EGFR-TKI (China Cohort)63
Values in Unit on scale · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Osimertinib 80 mg (Global Cohort)-4.13Not reported-6.35-1.91Not reported
SoC EGFR-TKI (Global Cohort)-5.78Not reported-8.02-3.54Not reported
Osimertinib 80 mg (China Cohort)-1.73Not reported-6.052.58Not reported
SoC EGFR-TKI (China Cohort)-6.81Not reported-11.30-2.33Not reported
Fatigue, week 12

Analysis denominator · Participants

GroupSource count
Osimertinib 80 mg (Global Cohort)237
SoC EGFR-TKI (Global Cohort)210
Osimertinib 80 mg (China Cohort)65
SoC EGFR-TKI (China Cohort)61
Values in Unit on scale · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Osimertinib 80 mg (Global Cohort)-5.11Not reported-7.31-2.91Not reported
SoC EGFR-TKI (Global Cohort)-6.52Not reported-8.81-4.23Not reported
Osimertinib 80 mg (China Cohort)-5.40Not reported-9.51-1.29Not reported
SoC EGFR-TKI (China Cohort)-6.36Not reported-10.61-2.12Not reported
Fatigue, week 18

Analysis denominator · Participants

GroupSource count
Osimertinib 80 mg (Global Cohort)229
SoC EGFR-TKI (Global Cohort)214
Osimertinib 80 mg (China Cohort)61
SoC EGFR-TKI (China Cohort)60
Values in Unit on scale · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Osimertinib 80 mg (Global Cohort)-6.83Not reported-9.21-4.44Not reported
SoC EGFR-TKI (Global Cohort)-5.77Not reported-8.23-3.31Not reported
Osimertinib 80 mg (China Cohort)-6.64Not reported-11.26-2.03Not reported
SoC EGFR-TKI (China Cohort)-7.90Not reported-12.61-3.19Not reported
Fatigue, week 24

Analysis denominator · Participants

GroupSource count
Osimertinib 80 mg (Global Cohort)216
SoC EGFR-TKI (Global Cohort)195
Osimertinib 80 mg (China Cohort)57
SoC EGFR-TKI (China Cohort)57
Values in Unit on scale · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Osimertinib 80 mg (Global Cohort)-6.18Not reported-8.75-3.61Not reported
SoC EGFR-TKI (Global Cohort)-4.96Not reported-7.63-2.28Not reported
Osimertinib 80 mg (China Cohort)-8.92Not reported-13.30-4.54Not reported
SoC EGFR-TKI (China Cohort)-3.87Not reported-8.320.58Not reported
Fatigue, week 30

Analysis denominator · Participants

GroupSource count
Osimertinib 80 mg (Global Cohort)207
SoC EGFR-TKI (Global Cohort)178
Osimertinib 80 mg (China Cohort)57
SoC EGFR-TKI (China Cohort)56
Values in Unit on scale · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Osimertinib 80 mg (Global Cohort)-5.19Not reported-7.94-2.43Not reported
SoC EGFR-TKI (Global Cohort)-3.26Not reported-6.16-0.35Not reported
Osimertinib 80 mg (China Cohort)-4.43Not reported-9.530.68Not reported
SoC EGFR-TKI (China Cohort)-6.31Not reported-11.53-1.10Not reported
Fatigue, week 36

Analysis denominator · Participants

GroupSource count
Osimertinib 80 mg (Global Cohort)193
SoC EGFR-TKI (Global Cohort)158
Osimertinib 80 mg (China Cohort)55
SoC EGFR-TKI (China Cohort)50
Values in Unit on scale · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Osimertinib 80 mg (Global Cohort)-5.47Not reported-8.31-2.63Not reported
SoC EGFR-TKI (Global Cohort)-2.00Not reported-2.001.04Not reported
Osimertinib 80 mg (China Cohort)-6.78Not reported-12.38-1.19Not reported
SoC EGFR-TKI (China Cohort)-3.46Not reported-9.282.36Not reported
Appetite Loss, First 9 months

Analysis denominator · Participants

GroupSource count
Osimertinib 80 mg (Global Cohort)252
SoC EGFR-TKI (Global Cohort)247
Osimertinib 80 mg (China Cohort)68
SoC EGFR-TKI (China Cohort)63
Values in Unit on scale · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Osimertinib 80 mg (Global Cohort)-6.15Not reported-8.39-3.90Not reported
SoC EGFR-TKI (Global Cohort)-5.64Not reported-7.96-3.32Not reported
Osimertinib 80 mg (China Cohort)1.18Not reported-2.785.14Not reported
SoC EGFR-TKI (China Cohort)-1.73Not reported-5.802.34Not reported
Appetite Loss, week 6

Analysis denominator · Participants

GroupSource count
Osimertinib 80 mg (Global Cohort)239
SoC EGFR-TKI (Global Cohort)236
Osimertinib 80 mg (China Cohort)68
SoC EGFR-TKI (China Cohort)63
Values in Unit on scale · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Osimertinib 80 mg (Global Cohort)-4.54Not reported-7.36-1.72Not reported
SoC EGFR-TKI (Global Cohort)-5.67Not reported-8.52-2.83Not reported
Osimertinib 80 mg (China Cohort)3.20Not reported-1.608.01Not reported
SoC EGFR-TKI (China Cohort)-6.27Not reported-11.26-1.27Not reported
Appetite Loss, week 12

Analysis denominator · Participants

GroupSource count
Osimertinib 80 mg (Global Cohort)237
SoC EGFR-TKI (Global Cohort)210
Osimertinib 80 mg (China Cohort)65
SoC EGFR-TKI (China Cohort)61
Values in Unit on scale · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Osimertinib 80 mg (Global Cohort)-6.52Not reported-9.43-3.62Not reported
SoC EGFR-TKI (Global Cohort)-6.95Not reported-9.98-3.91Not reported
Osimertinib 80 mg (China Cohort)1.58Not reported-3.236.39Not reported
SoC EGFR-TKI (China Cohort)-1.44Not reported-6.413.53Not reported
Appetite Loss, week 18

Analysis denominator · Participants

GroupSource count
Osimertinib 80 mg (Global Cohort)229
SoC EGFR-TKI (Global Cohort)214
Osimertinib 80 mg (China Cohort)61
SoC EGFR-TKI (China Cohort)60
Values in Unit on scale · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Osimertinib 80 mg (Global Cohort)-7.27Not reported-10.09-4.45Not reported
SoC EGFR-TKI (Global Cohort)-6.84Not reported-9.75-3.92Not reported
Osimertinib 80 mg (China Cohort)1.42Not reported-4.387.22Not reported
SoC EGFR-TKI (China Cohort)-4.43Not reported-10.351.48Not reported
Appetite Loss, week 24

Analysis denominator · Participants

GroupSource count
Osimertinib 80 mg (Global Cohort)216
SoC EGFR-TKI (Global Cohort)195
Osimertinib 80 mg (China Cohort)57
SoC EGFR-TKI (China Cohort)57
Values in Unit on scale · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Osimertinib 80 mg (Global Cohort)-7.14Not reported-10.27-4.01Not reported
SoC EGFR-TKI (Global Cohort)-5.08Not reported-8.35-1.81Not reported
Osimertinib 80 mg (China Cohort)-2.26Not reported-7.743.22Not reported
SoC EGFR-TKI (China Cohort)0.24Not reported-5.295.78Not reported
Appetite Loss, week 30

Analysis denominator · Participants

GroupSource count
Osimertinib 80 mg (Global Cohort)207
SoC EGFR-TKI (Global Cohort)178
Osimertinib 80 mg (China Cohort)57
SoC EGFR-TKI (China Cohort)56
Values in Unit on scale · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Osimertinib 80 mg (Global Cohort)-4.50Not reported-7.74-1.26Not reported
SoC EGFR-TKI (Global Cohort)-4.17Not reported-7.60-0.74Not reported
Osimertinib 80 mg (China Cohort)2.19Not reported-3.287.65Not reported
SoC EGFR-TKI (China Cohort)-1.83Not reported-7.363.70Not reported
Appetite Loss, week 36

Analysis denominator · Participants

GroupSource count
Osimertinib 80 mg (Global Cohort)193
SoC EGFR-TKI (Global Cohort)158
Osimertinib 80 mg (China Cohort)55
SoC EGFR-TKI (China Cohort)50
Values in Unit on scale · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Osimertinib 80 mg (Global Cohort)-6.90Not reported-10.00-3.81Not reported
SoC EGFR-TKI (Global Cohort)-5.15Not reported-8.49-1.81Not reported
Osimertinib 80 mg (China Cohort)0.98Not reported-5.287.24Not reported
SoC EGFR-TKI (China Cohort)3.36Not reported-3.159.86Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        -7.45
        upper Limit
        -3.52
        value
        -5.48
      2. group Id
        OG001
        lower Limit
        -6.74
        upper Limit
        -2.69
        value
        -4.72
      3. group Id
        OG002
        lower Limit
        -9.33
        upper Limit
        -1.98
        value
        -5.65
      4. group Id
        OG003
        lower Limit
        -9.58
        upper Limit
        -2.00
        value
        -5.79
    denoms
    1. counts
      1. group Id
        OG000
        value
        252
      2. group Id
        OG001
        value
        247
      3. group Id
        OG002
        value
        68
      4. group Id
        OG003
        value
        63
      units
      Participants
    title
    Fatigue, First 9 months
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        -6.35
        upper Limit
        -1.91
        value
        -4.13
      2. group Id
        OG001
        lower Limit
        -8.02
        upper Limit
        -3.54
        value
        -5.78
      3. group Id
        OG002
        lower Limit
        -6.05
        upper Limit
        2.58
        value
        -1.73
      4. group Id
        OG003
        lower Limit
        -11.30
        upper Limit
        -2.33
        value
        -6.81
    denoms
    1. counts
      1. group Id
        OG000
        value
        239
      2. group Id
        OG001
        value
        236
      3. group Id
        OG002
        value
        68
      4. group Id
        OG003
        value
        63
      units
      Participants
    title
    Fatigue, week 6
  3. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        -7.31
        upper Limit
        -2.91
        value
        -5.11
      2. group Id
        OG001
        lower Limit
        -8.81
        upper Limit
        -4.23
        value
        -6.52
      3. group Id
        OG002
        lower Limit
        -9.51
        upper Limit
        -1.29
        value
        -5.40
      4. group Id
        OG003
        lower Limit
        -10.61
        upper Limit
        -2.12
        value
        -6.36
    denoms
    1. counts
      1. group Id
        OG000
        value
        237
      2. group Id
        OG001
        value
        210
      3. group Id
        OG002
        value
        65
      4. group Id
        OG003
        value
        61
      units
      Participants
    title
    Fatigue, week 12
  4. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        -9.21
        upper Limit
        -4.44
        value
        -6.83
      2. group Id
        OG001
        lower Limit
        -8.23
        upper Limit
        -3.31
        value
        -5.77
      3. group Id
        OG002
        lower Limit
        -11.26
        upper Limit
        -2.03
        value
        -6.64
      4. group Id
        OG003
        lower Limit
        -12.61
        upper Limit
        -3.19
        value
        -7.90
    denoms
    1. counts
      1. group Id
        OG000
        value
        229
      2. group Id
        OG001
        value
        214
      3. group Id
        OG002
        value
        61
      4. group Id
        OG003
        value
        60
      units
      Participants
    title
    Fatigue, week 18
  5. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        -8.75
        upper Limit
        -3.61
        value
        -6.18
      2. group Id
        OG001
        lower Limit
        -7.63
        upper Limit
        -2.28
        value
        -4.96
      3. group Id
        OG002
        lower Limit
        -13.30
        upper Limit
        -4.54
        value
        -8.92
      4. group Id
        OG003
        lower Limit
        -8.32
        upper Limit
        0.58
        value
        -3.87
    denoms
    1. counts
      1. group Id
        OG000
        value
        216
      2. group Id
        OG001
        value
        195
      3. group Id
        OG002
        value
        57
      4. group Id
        OG003
        value
        57
      units
      Participants
    title
    Fatigue, week 24
  6. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        -7.94
        upper Limit
        -2.43
        value
        -5.19
      2. group Id
        OG001
        lower Limit
        -6.16
        upper Limit
        -0.35
        value
        -3.26
      3. group Id
        OG002
        lower Limit
        -9.53
        upper Limit
        0.68
        value
        -4.43
      4. group Id
        OG003
        lower Limit
        -11.53
        upper Limit
        -1.10
        value
        -6.31
    denoms
    1. counts
      1. group Id
        OG000
        value
        207
      2. group Id
        OG001
        value
        178
      3. group Id
        OG002
        value
        57
      4. group Id
        OG003
        value
        56
      units
      Participants
    title
    Fatigue, week 30
  7. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        -8.31
        upper Limit
        -2.63
        value
        -5.47
      2. group Id
        OG001
        lower Limit
        -2.00
        upper Limit
        1.04
        value
        -2.00
      3. group Id
        OG002
        lower Limit
        -12.38
        upper Limit
        -1.19
        value
        -6.78
      4. group Id
        OG003
        lower Limit
        -9.28
        upper Limit
        2.36
        value
        -3.46
    denoms
    1. counts
      1. group Id
        OG000
        value
        193
      2. group Id
        OG001
        value
        158
      3. group Id
        OG002
        value
        55
      4. group Id
        OG003
        value
        50
      units
      Participants
    title
    Fatigue, week 36
  8. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        -8.39
        upper Limit
        -3.90
        value
        -6.15
      2. group Id
        OG001
        lower Limit
        -7.96
        upper Limit
        -3.32
        value
        -5.64
      3. group Id
        OG002
        lower Limit
        -2.78
        upper Limit
        5.14
        value
        1.18
      4. group Id
        OG003
        lower Limit
        -5.80
        upper Limit
        2.34
        value
        -1.73
    denoms
    1. counts
      1. group Id
        OG000
        value
        252
      2. group Id
        OG001
        value
        247
      3. group Id
        OG002
        value
        68
      4. group Id
        OG003
        value
        63
      units
      Participants
    title
    Appetite Loss, First 9 months
  9. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        -7.36
        upper Limit
        -1.72
        value
        -4.54
      2. group Id
        OG001
        lower Limit
        -8.52
        upper Limit
        -2.83
        value
        -5.67
      3. group Id
        OG002
        lower Limit
        -1.60
        upper Limit
        8.01
        value
        3.20
      4. group Id
        OG003
        lower Limit
        -11.26
        upper Limit
        -1.27
        value
        -6.27
    denoms
    1. counts
      1. group Id
        OG000
        value
        239
      2. group Id
        OG001
        value
        236
      3. group Id
        OG002
        value
        68
      4. group Id
        OG003
        value
        63
      units
      Participants
    title
    Appetite Loss, week 6
  10. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        -9.43
        upper Limit
        -3.62
        value
        -6.52
      2. group Id
        OG001
        lower Limit
        -9.98
        upper Limit
        -3.91
        value
        -6.95
      3. group Id
        OG002
        lower Limit
        -3.23
        upper Limit
        6.39
        value
        1.58
      4. group Id
        OG003
        lower Limit
        -6.41
        upper Limit
        3.53
        value
        -1.44
    denoms
    1. counts
      1. group Id
        OG000
        value
        237
      2. group Id
        OG001
        value
        210
      3. group Id
        OG002
        value
        65
      4. group Id
        OG003
        value
        61
      units
      Participants
    title
    Appetite Loss, week 12
  11. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        -10.09
        upper Limit
        -4.45
        value
        -7.27
      2. group Id
        OG001
        lower Limit
        -9.75
        upper Limit
        -3.92
        value
        -6.84
      3. group Id
        OG002
        lower Limit
        -4.38
        upper Limit
        7.22
        value
        1.42
      4. group Id
        OG003
        lower Limit
        -10.35
        upper Limit
        1.48
        value
        -4.43
    denoms
    1. counts
      1. group Id
        OG000
        value
        229
      2. group Id
        OG001
        value
        214
      3. group Id
        OG002
        value
        61
      4. group Id
        OG003
        value
        60
      units
      Participants
    title
    Appetite Loss, week 18
  12. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        -10.27
        upper Limit
        -4.01
        value
        -7.14
      2. group Id
        OG001
        lower Limit
        -8.35
        upper Limit
        -1.81
        value
        -5.08
      3. group Id
        OG002
        lower Limit
        -7.74
        upper Limit
        3.22
        value
        -2.26
      4. group Id
        OG003
        lower Limit
        -5.29
        upper Limit
        5.78
        value
        0.24
    denoms
    1. counts
      1. group Id
        OG000
        value
        216
      2. group Id
        OG001
        value
        195
      3. group Id
        OG002
        value
        57
      4. group Id
        OG003
        value
        57
      units
      Participants
    title
    Appetite Loss, week 24
denoms
  1. counts
    1. group Id
      OG000
      value
      279
    2. group Id
      OG001
      value
      277
    3. group Id
      OG002
      value
      71
    4. group Id
      OG003
      value
      65
    units
    Participants
description
The EORTC QLQ-C30 cancer-specific questionnaire consisted of 30 questions, combined to produce 5 functional scales, 3 symptom scales, 6 individual items, and a global measure of health status/QoL. An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items, the functional scales, and the global health status/QoL scale in the EORTC QLQ-C30. Higher scores on the global health status and functioning scales indicated better health status/function. Higher scores on the symptoms scales indicated greater symptom burden. The analysis was performed using a Mixed-effects model for repeated measures analysis on the change from baseline in PRO symptom score at each visit up to 9 months (281 days), including participants, treatment, visit and treatment by visit interaction as explanatory variables, the baseline PRO score as a covariate along with the baseline PRO score by visit interaction, using an unstructured covariance structure.
dispersion Type
95% Confidence Interval
groups
  1. description
    Randomized participants received Osimertinib 80 mg orally once daily (QD)
    id
    OG000
    title
    Osimertinib 80 mg (Global Cohort)
  2. description
    Randomized participant received Standard of care (SoC) Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Participants received gefitinib 250 mg orally QD or erlotinib 150 mg orally QD.
    id
    OG001
    title
    SoC EGFR-TKI (Global Cohort)
  3. description
    Randomized participants received Osimertinib 80 mg orally once daily (QD)
    id
    OG002
    title
    Osimertinib 80 mg (China Cohort)
  4. description
    Randomized participant received Standard of care (SoC) Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFRTKI). Participants received gefitinib 250 mg orally QD or erlotinib 150 mg orally QD.
    id
    OG003
    title
    SoC EGFR-TKI (China Cohort)
param Type
LEAST_SQUARES_MEAN
population Description
The full analysis set (FAS) and China-only FAS. FAS included all randomized participants prior to the end of global recruitment. The China-only FAS included all China participants randomized in mainland-China as part of the global study and all additional China participants recruited in mainland China after global recruitment was completed.
reporting Status
POSTED
time Frame
Questionnaires completed at baseline, first 9 months, and at week 6, 12, 18, 24, 30, and 36.
title
Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Items (EORTC QLQ-C30)
type
SECONDARY
unit Of Measure
Unit on scale

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice